IXI IXICO plc

LSE · GB · Healthcare · Biotechnology · ixico.com

7.500GBP0.00%Mkt Cap: 21.06M $P/E: —3d ago

IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. The company offers collectio…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

$23.37BUSDP/E 14.7

GMAB

Genmab A/S - American Depositary Shares

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap21.06M USD

Enterprise Value7.48M USD

Revenue (TTM)9.33M USD

Gross Profit4.08M USD

Net Income (TTM)-2.12M USD

Revenue/Share0.08 GBP

Last Price7.500 GBP

Fiscal Year EndSep 2025

MR QuarterMar 2026

Employees79

CountryGB

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-5.77

PEG—

EV/EBITDA-2.19

EV/Revenue0.80

P/S2.26

P/B0.65

EPS (TTM)-0.02

EPS (Forward)-0.01

52W Range

6.26014% of range15.00

52W High15.00 GBP

52W Low6.260 GBP

Profitability

Gross Margin48.71%

Oper. Margin-31.43%

EBITDA Margin-36.67%

Profit Margin-25.27%

ROE-14.07%

ROA-11.93%

Growth

Revenue Growth23.10%

Earnings Growth—

Cash Flow & Leverage

Operating CF-1.29M USD

CapEx (TTM)1.12M USD

FCF Margin-43.73%

FCF Yield-19.37%

Net Debt-1.43M USD

Net Debt/EBITDA0.42

Balance Sheet

Debt/Equity0.02

Current Ratio2.83

Quick Ratio2.83

Book Value/Sh0.12 GBP

Cash/Share0.02 GBP

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 GBP

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Splits

Last Split1:50

Split DateSep 4, 2013

Analyst Consensus

Rating—

Target (Mean)26.00 GBP

Upside (mean)+246.7%

Target Range26.00 GBP – 26.00 GBP

# Analysts1

Ownership

Shares Out.218.97M

Float40.77M

Insiders4.55%

Institutions82.55%

Technical

SMA 507.668 (-2.2%)

SMA 2008.434 (-11.1%)

Beta0.11

S&P 52W Chg14.58%

Avg Vol (30d)48.74K

Avg Vol (10d)64.31K

Technical Indicators

RSI (14)40.2

MACD-0.0786

MACD Signal-0.1053

MACD Hist.+0.0267

BB Upper7.540 GBP

BB Middle7.495 GBP

BB Lower7.450 GBP

BB Width1.19%

ATR (14)0.6680 GBP

Vol Ratio (20d)0.20x